Maternal RSV vaccine cuts infant hospitalizations by 70%
_-_52456179236.jpg){kind=link}
A study has found that vaccination against respiratory syncytial virus (RSV) during pregnancy reduced the risk of hospitalization in young infants by nearly 70%. It provides early real-world evidence from U.S. clinical care, showing that administering one dose of the maternal RSV vaccine (RSVpreF vaccine) reduces hospitalization related to RSV in young infants.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.